Position
FINANCIAL CONSULATE, INC in Vaxcyte, Inc.
Back to the book · All holders of PCVX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $2.99K$46.14 → $58.11
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 250 | $11.5K | — | — | — | 0.0% |
| Q1 2026 | 250 | $14.5K | $58.11 | $2.99K | −$0 | 0.0% |